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1. CASE {#ccr32487-sec-0001}
=======

Internal tandem duplication mutations of the *FLT3* gene (*FLT3*‐ITD) are commonly acquired mutations in acute myeloid leukemia (AML) and are associated with a high risk of relapse. The FLT3 inhibitor sorafenib has been evaluated in *FLT3*‐mutated AML postallogeneic stem cell transplantation (alloSCT).[1](#ccr32487-bib-0001){ref-type="ref"}

A 60‐year‐old man diagnosed with *FLT3*‐ITD‐positive AML in second remission underwent a sibling donor alloSCT. On Day +59, an extensive papular rash developed on his lower back, thought most likely to represent acute Graft‐Versus‐Host disease. However, skin biopsy demonstrated an infiltrate of myeloblasts consistent with leukemia cutis (Figure [1](#ccr32487-fig-0001){ref-type="fig"}A and 1B) that was *FLT3*‐ITD mutation positive. On Day +71, he started sorafenib monotherapy (400 mg BD) resulting in a substantial clinical improvement after two weeks (Figure [2](#ccr32487-fig-0002){ref-type="fig"}A and 2B). A donor lymphocyte infusion was administered on Day + 122 for bone marrow relapse resulting in a remission of several months until he relapsed and died on Day + 505.

![A, Skin biopsy showing dermal infiltration of myeloblasts (hematoxylin and eosin, ×200). B, Myeloblasts staining positive for myeloperoxidase (×200)](CCR3-7-2579-g001){#ccr32487-fig-0001}

![A, Presentation of leukemia cutis. B, Response after two weeks of sorafenib therapy](CCR3-7-2579-g002){#ccr32487-fig-0002}

Sorafenib for relapsed *FLT3*‐ITD‐positive AML presenting as leukemia cutis has rarely been described.[2](#ccr32487-bib-0002){ref-type="ref"} This case highlights the need to consider leukemia cutis in the differential diagnosis of a rash early post‐alloSCT and the rapidity of the response that can be achieved with sorafenib.
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